Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (16899)	5/23/2005 10:41:46 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

On Vivitrex you say: In short, Vivitrex seems to work, but a monthly saline injection may work almost as well. The fact is that Vivitrex showed a statistically significant effect: Compared with placebo, 380 mg of long-acting naltrexone resulted in a 25% decrease in the event rate of heavy drinking days (P = .02) For men (who form the bulk of the relevant population), the effect was quite a bit stronger (hazard ration .56, with p value < .001). I grant you the Barrons article (and the ALKS PR) are misleading in citing the drop without mentioning the drop in placebo as well, but the fact is the drug clearly works (much to my surprise). The fact is that right now there is no acceptable medical treatment - to argue that because the co-therapy provided most of the benefit that therefore the drug has no merit is incorrect in my view. Peter